GlassScriptPhysician profile
Anil Sangwan
NPI 1083728323
$9,525.10
in general payments reported to CMS, 2019-2025
49 companies · $2,213 in 2025
The $2,213 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.45 · 2020: $149 · 2021: $1,282 · 2022: $1,654 · 2023: $1,921 · 2024: $2,274 · 2025: $2,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,408.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,088.39 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $762.49 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $702.31 | 2023-2025 | |
| Lilly USA, LLC | $695.85 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $643.80 | 2021-2025 | Ubrelvy, Qulipta, Synthroid |
| Regeneron Healthcare Solutions, INC. | $640.52 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $606.97 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $535.09 | 2021-2025 | Jardiance, Synjardy, Ofev |
| Merck Sharp & Dohme LLC | $423.78 | 2022-2025 | Verquvo, Dificid, Steglatro |
| Pfizer INC. | $326.69 | 2021-2025 | |
| Radius Health, INC. | $325.58 | 2020-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $243.40 | 2021-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $225.71 | 2022-2025 | |
| Abbott Laboratories | $206.27 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $172.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Sangwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.